logo
  

Lifecore Biomedical Falls On Approval Of Strategic Alternatives, Appointment Of CEO

Lifecore Biomedical, Inc. (LFCR) shares are falling more than 35 percent on Wednesday morning trade after the company announced approval for its review of strategic alternatives. The company also announced strategic updates related to its operations on a stand-alone basis. Further, the company named Paul Josephs as chief executive office to succeed James Hall on his retirement.

Currently, shares are at $4.71, down 34.49 percent from the previous close of $7.19 on a volume of 1,292,191.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
Follow RTT